·   Log in

Archive for November 4th, 2009

Pancreatic cancer drug TNFerade by GenVec to get speedy approval in US

Wednesday, November 4, 2009 20:40

TNFerade, an investigational drug against pancreatic cancer, has been awarded Orphan Drug status providing potential financial and regulatory incentives by the U.S. Food and Drug Administration, its maker GenVec announced in a press statement.

This was posted under category: Clinical Trials  |  Read Full Story  |  0 Comments

Aurobindo posts net profit of Rs 128.29 crore in Q2

Wednesday, November 4, 2009 14:39

India's Aurobindo Pharma posted net profit of Rs 128.29 crore in Q2 September 2009 as against a net loss of Rs 38.50 crore in the same quarter last year. Aurobindo Pharma's net sales rose 30% to Rs 826.31 crore in Q2 September 2009 over Q2 September 2008. During the quarter ended September ...

This was posted under category: Industry  |  Read Full Story  |  0 Comments

ADX10059 can stop movement disorder dystonia symptoms caused by levadopa in Parkinson’s disease: Addex Pharma

Wednesday, November 4, 2009 14:37

ADX10059, an experimental drug can block movement disorder dystonia symptoms induced by levodopa in Parkinson's disease patients, Addex Pharma said in a press statement.

This was posted under category: Discoveries  |  Read Full Story  |  0 Comments
Tagged with: ,

Vaccine to fight breast and lung cancer Stimuvax from Merck KgaA is coming

Wednesday, November 4, 2009 14:35

Stimuvax, an experimental therapeutic vaccine the stimulate immune cell to fight cancer from Merck KGaA of Germany, has been foundĀ  promising enough to treat several cancers including breast tumours and lung cancer.

This was posted under category: Clinical Trials  |  Read Full Story  |  0 Comments
Tagged with: ,

Emergency contraceptives pills like `i-pill’ of Cipla or `Unwanted 72′ of Mankind could be made prescription drugs

Wednesday, November 4, 2009 14:03

Media ads promoting morning after emergency contraceptive pills too are underĀ  scanner

This was posted under category: Consumer, Legal  |  Read Full Story  |  0 Comments